Myriam El Gaaloul

Head o Clinical Sciences & Regulatory

Medicines for Malaria Venture

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Myriam El Gaaloul is the Head of Clinical Sciences & Regulatory at Medicines for Malaria Venture in Switzerland. Her research focuses on advancing maternal and perinatal health through clinical trials, pharmacokinetics of antimalarial drugs, and health equity for breastfeeding women. She has contributed to multiple significant publications aimed at improving treatment strategies for malaria and addressing health challenges faced by vulnerable populations.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (4)

Louise Marquart

Senior Lecturer Biostatistics

University of Queensland

AUSTRALIA

View details

Sergi Sanz Bravo

Biostatistic, Head of Unit

Barcelona Institute for Global Health

SPAIN

View details

Heimo Lagler

Associate Professor

Medical University of Vienna

AUSTRIA

View details

Michael Ramharter

Professor

Bernhard-Nocht-Institut für Tropenmedizin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Myriam El Gaaloul

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Advancing maternal and perinatal health through clinical trials: key insights from a WHO global consultation

PBPK‐Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population

Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with <i>Plasmodium falciparum</i> Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study

Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.

Correction: Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile.

Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood-stage Plasmodium falciparum to predict efficacy in patients with malaria

Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile.

Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure.

Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.

Collaborators (4)

Louise Marquart

Sergi Sanz Bravo

Heimo Lagler

Michael Ramharter

Make your next move.